{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:50:45Z","timestamp":1789638645138,"version":"4.0.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":1323,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1093\/annonc\/mdw085","type":"journal-article","created":{"date-parts":[[2016,5,2]],"date-time":"2016-05-02T07:27:55Z","timestamp":1462174075000},"page":"i45-i49","source":"Crossref","is-referenced-by-count":80,"special_numbering":"S1","title":["Low-grade serous carcinoma of the ovary or peritoneum"],"prefix":"10.1016","volume":"27","author":[{"given":"D.M.","family":"Gershenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1093\/annonc\/mdw085_bb0010","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1093\/annonc\/mdw085_bb0015","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ygyno.2006.05.030","article-title":"Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum","volume":"103","author":"Seidman","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdw085_bb0020","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/PAS.0b013e31803199b0","article-title":"Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma","volume":"31","author":"Malpica","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1093\/annonc\/mdw085_bb0025","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/PAS.0b013e31816fd555","article-title":"Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data","volume":"32","author":"Vang","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1093\/annonc\/mdw085_bb0030","first-page":"1","article-title":"Ovarian low-grade and high-grade serous carcinoma","volume":"11","author":"Vang","year":"2009","journal-title":"Adv Anat Pathol"},{"issue":"12","key":"10.1093\/annonc\/mdw085_bb0035","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1002\/cncr.26618","article-title":"Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study","volume":"118","author":"Bodurka","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"10.1093\/annonc\/mdw085_bb0040","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/PGP.0000000000000135","article-title":"Low-grade serous tumors of ovary","volume":"33","author":"Bell","year":"2014","journal-title":"Int J Gynecol Pathol"},{"key":"10.1093\/annonc\/mdw085_bb0045","series-title":"WHO Classification of Tumours of Female Reproductive Organs","author":"Kurman","year":"2013"},{"issue":"1","key":"10.1093\/annonc\/mdw085_bb0050","first-page":"3","article-title":"Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential","volume":"99","author":"Crispens","year":"2002","journal-title":"Obstet Gynecol"},{"issue":"10","key":"10.1093\/annonc\/mdw085_bb0055","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2157::AID-CNCR14>3.0.CO;2-D","article-title":"Serous borderline tumors of the ovary with noninvasive peritoneal implants","volume":"83","author":"Gershenson","year":"1998","journal-title":"Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdw085_bb0060","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1096::AID-CNCR13>3.0.CO;2-1","article-title":"Ovarian serous borderline tumors with invasive peritoneal implants","volume":"82","author":"Gershenson","year":"1998","journal-title":"Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdw085_bb0065","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II\u2013IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1093\/annonc\/mdw085_bb0070","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ygyno.2007.01.030","article-title":"Comparison of the clinical behavior of newly diagnosed stages II\u2013IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma","volume":"105","author":"Shvartsman","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdw085_bb0075","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdw085_bb0080","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/sj.onc.1208298","article-title":"Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential","volume":"24","author":"Meinhold-Heerlein","year":"2004","journal-title":"Oncogene"},{"issue":"22","key":"10.1093\/annonc\/mdw085_bb0085","doi-asserted-by":"crossref","first-page":"10602","DOI":"10.1158\/0008-5472.CAN-05-2240","article-title":"Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary","volume":"65","author":"Bonome","year":"2005","journal-title":"Cancer Res"},{"issue":"8","key":"10.1093\/annonc\/mdw085_bb0090","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/01.pas.0000166367.68459.7d","article-title":"An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2\/neu, and C-KIT in high-grade neoplasms","volume":"29","author":"O'Neill","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1093\/annonc\/mdw085_bb0095","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/01.pas.0000146025.91953.8d","article-title":"Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation","volume":"29","author":"Singer","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1093\/annonc\/mdw085_bb0100","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/pgp.0b013e31803025cd","article-title":"Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis","volume":"26","author":"Wong","year":"2007","journal-title":"Int J Gynecol Pathol"},{"issue":"9","key":"10.1093\/annonc\/mdw085_bb0105","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/modpathol.2009.92","article-title":"PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas","volume":"22","author":"Tung","year":"2009","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1093\/annonc\/mdw085_bb0110","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/PAS.0b013e318212ae22","article-title":"The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer","volume":"35","author":"King","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1093\/annonc\/mdw085_bb0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ygyno.2011.06.016","article-title":"The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma","volume":"123","author":"King","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdw085_bb0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2407-8-17","article-title":"Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities","volume":"8","author":"Press","year":"2008","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdw085_bb0125","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2010.10.033","article-title":"Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?","volume":"120","author":"Vineyard","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdw085_bb0130","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","article-title":"Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma","volume":"95","author":"Singer","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1093\/annonc\/mdw085_bb0135","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2353\/ajpath.2010.100212","article-title":"BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas","volume":"177","author":"Wong","year":"2010","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1093\/annonc\/mdw085_bb0140","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdw085_bb0145","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cncr.27782","article-title":"BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer","volume":"119","author":"Grisham","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"10.1093\/annonc\/mdw085_bb0150","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/path.4252","article-title":"KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma","volume":"231","author":"Tsang","year":"2013","journal-title":"J Pathol"},{"key":"10.1093\/annonc\/mdw085_bb0155","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1158\/1078-0432.CCR-14-1292","article-title":"Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver","volume":"20","author":"Emmanuel","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1093\/annonc\/mdw085_bb0160","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.3967","article-title":"Low-grade serous carcinomas of the ovary contain very few point mutations","volume":"226","author":"Jones","year":"2011","journal-title":"J Pathol"},{"issue":"2, Part 1","key":"10.1093\/annonc\/mdw085_bb0165","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/AOG.0b013e31829ce7ec","article-title":"Survival in women with grade 1 serous ovarian carcinoma","volume":"122","author":"Fader","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1093\/annonc\/mdw085_bb0170","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2013.11.016","article-title":"The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a Gynecologic Oncology Group study","volume":"132","author":"Fader","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdw085_bb0175","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/IGC.0000000000000109","article-title":"Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer","volume":"24","author":"Previs","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdw085_bb0180","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ygyno.2011.02.017","article-title":"Low-grade serous primary peritoneal carcinoma","volume":"121","author":"Schmeler","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdw085_bb0185","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1200\/JCO.2015.61.0873","article-title":"Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor","volume":"33","author":"Gershenson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw085_bb0190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2014.11.005","article-title":"The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer","volume":"136","author":"Crane","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdw085_bb0195","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdw085_bb0200","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","article-title":"Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum","volume":"125","author":"Gershenson","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdw085_bb0205","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1093\/annonc\/mdw085_bb0210","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1078-0432.CCR-07-4790","article-title":"Advances in targeting the Ras\/Raf\/MEK\/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy","volume":"14","author":"Friday","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1093\/annonc\/mdw085_bb0215","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1158\/1535-7163.MCT-11-0505","article-title":"Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212","volume":"11","author":"Jing","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1093\/annonc\/mdw085_bb0220","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.pharmthera.2013.10.001","article-title":"MEK in cancer and cancer therapy","volume":"141","author":"Neuzillet","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1093\/annonc\/mdw085_bb0225","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ygyno.2014.01.008","article-title":"MEK1\/2 inhibitors in the treatment of gynecologic malignancies","volume":"133","author":"Miller","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdw085_bb0230","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1158\/0008-5472.CAN-04-3625","article-title":"Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations","volume":"65","author":"Pohl","year":"2005","journal-title":"Cancer Res"},{"issue":"12","key":"10.1093\/annonc\/mdw085_bb0235","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/sj.bjc.6604783","article-title":"KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer","volume":"99","author":"Nakayama","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdw085_bb0240","first-page":"4726","article-title":"Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer","volume":"62","author":"Grisham","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw085_bb0245","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw085_bb0250","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ygyno.2006.03.048","article-title":"Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms","volume":"102","author":"Bidus","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdw085_bb0255","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/IGC.0000000000000190","article-title":"Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer","volume":"24","author":"Grisham","year":"2014","journal-title":"Int J Gynecol Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341931614X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341931614X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/suppl_1\/i45\/19446891\/mdw085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T15:11:08Z","timestamp":1655651468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341931614X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":50,"alternative-id":["S092375341931614X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw085","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}